

# VDP Spring 2023 Campaign Eligible Cohorts for COVID-19 Vaccines

Version 4.1

27 MARCH 2023

Correct at time of publication, see [Future NHS Workspace](#) for latest version

Contents

Page 2    Seasonal Booster and Primary Course Offer



## Seasonal booster: Spring 2023 Individual must have completed a primary course of 2 or 3 doses AND previous dose must have been at least 91 days ago

### Eligible cohorts As recommended by JCVI

- Adult aged 75<sup>♦</sup> years and over, irrespective of place of residence
- A resident (of any age) in a care home for older adults<sup>♦</sup>
- Individuals aged 5 years and over who are immunosuppressed (as defined in the 'Immunosuppression' rows of Tables 3 and 4 in the [Green Book, Chapter 14a](#))

Age group	Recommended vaccine and dose volume
75 <sup>♦</sup> years and over Residents aged 65 years and over AND residing in care homes for older adults <sup>♦</sup>	VidPrevtyn Beta (0.5mL mixed dose) <b>OR</b> Comirnaty Original/Omicron BA.4-5 (0.3mL dose)
12 years and over	Comirnaty Original/Omicron BA.4-5 (0.3mL dose)
5 to 11 years	Comirnaty 10 Concentrate (0.2mL diluted dose)
<sup>♦</sup> Those individuals who will turn 75 years of age by 30 June 2023 can be vaccinated at any point in the campaign	<sup>♦</sup> Care home for older adults as defined through CQC registration

## Primary course offer: individuals yet to complete their primary offer If eligible for a Spring booster, refer to seasonal booster table above after completing primary course

Eligible cohort (See <a href="#">Green Book Chapter 14a</a> for full clinical details)	Primary course (2 doses*): recommended vaccine and dose volume
12 <sup>■</sup> years or over	Comirnaty Original/Omicron BA.4-5 (0.3mL dose)
5 <sup>†</sup> – 11 years	Comirnaty 10 Concentrate (0.2mL diluted dose)
<sup>†</sup> For those not in a risk group, this one off offer only applies to individuals who turned 5 by 31 August 2022	<sup>■</sup> 12 year olds who started their primary course with Comirnaty 10 Concentrate can complete the course with this vaccine or with Comirnaty Original/Omicron BA.4-5
	<sup>*</sup> Severely immunosuppressed at the time of 1st or 2nd primary dose: 2 primary doses PLUS 3rd primary dose ideally 8 weeks after 2nd dose

### Additional information: (see the clinical section of the [COVID-19 Vaccination Bulletin](#) from 23 March and [Green Book, Chapter 14a](#) for more details)

- If an individual eligible for a booster in Spring 2023 has not received a previous booster, they may be given one during the campaign, and no additional doses are then required.
- For those aged 18 or over, OR aged 5 or over and are in a risk group, the interval between 1<sup>st</sup> and 2<sup>nd</sup> primary dose is recommended as 8 weeks.
- For those aged 5-17 years and not in a risk group, the interval between 1<sup>st</sup> and 2<sup>nd</sup> primary dose is recommended as 12 weeks
- There is no need to defer immunisation in individuals after recovery from a recent episode of suspected or confirmed COVID-19 infection. Vaccination can be offered if clinically well.
- Patient Group Directions (PGD) and National Protocols are available [here](#). A local Patient Specific Direction (PSD) can also be used.
- Vaccine handling guidance and template SOPs are available [here](#).
- Most individuals can receive an mRNA vaccine. For those exceptional circumstances where an individual aged 12 years and over is unable to safely receive an mRNA vaccine for clinical reasons, Nuvaxovid is available at selected sites via a prescriber (PSD only). VidPrevtyn Beta can be considered in those aged 65 years and over.